Comparison
Piracetam vs CDP-Choline
Piracetam
The original nootropic, developed in 1964 by Romanian chemist Corneliu Giurgea. A cyclic derivative of GABA and the founding member of the racetam family.
CDP-Choline
Cytidine 5'-diphosphocholine. Delivers both choline (for acetylcholine synthesis) and cytidine (for uridine and synaptic membrane synthesis), giving it a dual mechanism that distinguishes it from Alpha-GPC. The most-validated choline source for stroke recovery and age-related cognitive decline.
| Field | Piracetam | CDP-Choline |
|---|---|---|
| Category | racetam | cholinergic |
| Dose range | 1200–4800mg | 250–500mg |
| Half-life | 5h | 56h |
| Onset | 45min | 60min |
| Evidence | EVIDENCEA | EVIDENCEA |
| Safety | ●●●●● | ●●●●● |
| Legal (US) | USUnscheduled | USOTC |
| PubMed refs | 1200 | 420 |
The comparison in plain English
Auto-generated from dataPiracetam and CDP-Choline are both in the racetam (racetam) and cholinergic respectively. Piracetam The original nootropic, developed in 1964 by Romanian chemist Corneliu Giurgea. CDP-Choline Cytidine 5'-diphosphocholine.
Bottom line
Piracetam (evidence A, safety 5/5) matches the evidence base of CDP-Choline (evidence A, safety 5/5). Piracetam has the slightly cleaner safety profile. For users new to either, the higher-evidence option is the safer first try.
Choose Piracetam if
Piracetam is the better fit when your goal aligns with its mechanism (Modulates AMPA and NMDA glutamate receptors and enhances acetylcholine signaling via muscarinic receptor allosteric modulation) and the dose range (1200–4800mg) suits your protocol. Half-life is 5h.
Choose CDP-Choline if
CDP-Choline is the better fit when your goal aligns with its mechanism (Hydrolysed into choline and cytidine in the gut) and the dose range (250–500mg) suits your protocol. Half-life is 56h.